CP and neoplasm: Talazoparib not only reduced tumor growth as a single agent but inhibited tumor growth virtually completely when used in combination with cisplatin (talazoparib alone 824.57 ± 41.2 mm3, p = 0.0061 vs. CP+Talazoparib 333.95 ± 16.65 mm3, p = 0.0018) (Fig. 5D).